查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715471

帕金森氏症药物市场按药物类别、给药途径、剂型、目标区域和分销管道划分－2025-2030 年全球预测

Parkinson's Disease Therapeutics Market by Drug Class, Route Of Administration, Drug Form, Targeted Area, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

帕金森氏症药物市场预计到 2024 年将达到 58.1 亿美元，2025 年将达到 61.4 亿美元，到 2030 年将达到 82.1 亿美元，复合年增长率为 5.93%。

主要市场统计数据
基准年2024年 58.1亿美元
预计2025年 61.4亿美元
预测年份 2030 82.1亿美元
复合年增长率（%） 5.93%

帕金森氏症是最具挑战性的神经退化性疾病之一，需要不断创新治疗方法。近年来，研究和临床试验取得了渐进式和突破性的进展，不仅解决了这种复杂疾病的运动症状，而且解决了非运动方面的问题。治疗方法的进步正在开启一个新时代，精准医疗和个人化治疗计画将越来越成为病患照护不可或缺的一部分。透过更了解疾病途径、改进诊断技术和旨在减少副作用和改善患者预后的新型药物传递方法，目前的治疗模式得到了增强。

本介绍为深入讨论影响帕金森氏症药物的多方面动态奠定了基础。值得注意的是，临床医生、研究人员和行业专家之间的持续合作对于确定未来的治疗策略至关重要。透过形成全面的观点，相关人员可以更好地预测监管要求、报销模式和患者期望的变化。科学技术的融合正在重新定义治疗流程，并为患者和看护者带来希望。本摘要概述了变革性转变、细分洞察、全球区域动态、有影响力的市场参与者以及有助于在这个不断发展的领域进行策略决策的可行建议，为您进入后续章节提供了必要的背景资讯。

改变帕金森氏症药物市场

近年来，帕金森氏症的治疗发生了变革性的变化，重塑了旧的治疗模式并引入了创新的治疗方法。这种转变是由突破性的研究带来的，它重新定义了我们思考和提供治疗性介入的方式。神经药理学的进步现在可以更有针对性地调节多巴胺能係统，新技术正在提高药物传递的精确度。推动这股势头的是临床试验设计的改进，更重视长期疗效和安全性。

同时，对疾病异质性的深入了解也迫使临床医师重新思考其一刀切的治疗方法。该行业目前专注于考虑到患者独特的基因和症状特征的个人化治疗方法。这种个人化不仅优化了临床结果，而且还有助于减少与传统治疗方法相关的副作用。此外，数位健康解决方案和远端患者监护对于管理疾病进展变得至关重要，使临床医生能够近乎即时地调整治疗策略。学术机构和生物技术公司之间的合作正在迅速缩小实验室发现和临床应用之间的差距，为帕金森氏症药物前所未有的成长和创新时代奠定了基础。

按市场区隔的关键见解

帕金森氏症治疗领域的市场细分为了解治疗策略如何多样化以满足特定患者的需求提供了重要的见解。依药物类别细分研究治疗方案，例如抗胆碱能药物、碳度巴-左旋多巴、COMT 抑制剂、多巴胺促效剂和 MAO-B 抑制剂。这种分类有助于细緻地了解不同类别如何发挥不同的治疗效果以及如何针对特定患者情况进行最佳化。

此外，按给药途径细分突显了肠内注射、口服技术、皮下注射和局部应用在实现理想药物动力学特征方面所扮演的重要角色。依药物形式进一步细分，可揭示注射剂、锭剂、胶囊、经皮吸收贴片剂型对患者依从性和疗效的影响。此外，非典型帕金森氏症、药物性帕金森氏症、遗传性帕金森氏症、特发性帕金森氏症和血管性帕金森氏症相关治疗的主题区域细分突显了疾病的不同表现如何需要不同的治疗途径。最后，对分销管道的细分，评估医院药房、线上药房和零售药房，说明了不断变化的消费行为和医疗保健服务模式的适应性，以确保更广泛的覆盖范围。

这种详细的细分凸显了该行业提高精准度、更有效地客製化治疗方法以及最终改善患者照护整体轨蹟的动力。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 随着全球老龄人口的增加，帕金森氏症的发生率也增加
      • 透过生物标记识别和基因监测实现个人化医疗方法的出现
      • 增强医疗保健基础设施并改善专科神经病学中心的可及性
    • 限制因素
      • 副作用风险高，降低病患依从性和整体接受度
    • 机会
      • 整合人工智慧演算法和巨量资料分析，优化个人化治疗的预测模型
      • 增加对早期诊断检测和先进成像技术的投资将有助于及时发现
    • 任务
      • 不同地区的法规结构复杂且合规标准严格
  • 市场区隔分析
    • 药物类别：Lovopoda 类药物越来越受到青睐，可以增加进入大脑的左旋多巴的量
    • 重点领域：阐明药物对药物性帕金森氏症引起的神经系统影响
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 帕金森氏症药物市场（依药物类别）

  • 抗胆碱药物
  • Carbidopa-Levodopa
  • COMT抑制剂
  • 促效剂
  • MAO-B抑制剂

7. 帕金森氏症药物市场（依给药途径）

  • 肠道注射
  • 口服
  • 皮下
  • 话题

第 8 章：帕金森氏症药物市场（以药物剂型）

  • 注射
  • 锭剂和胶囊
  • 经皮吸收贴片

第九章帕金森氏症药物市场（按目标区域）

  • 非典型帕金森氏症
  • 药物引起的帕金森氏症
  • 遗传性帕金森氏症
  • 特发性帕金森氏症
  • 血管性帕金森氏症

第 10 章帕金森氏症药物市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第 11 章：美洲帕金森氏症药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太帕金森氏症药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲帕金森氏症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Biogen Inc
  • Bristol-Myers Squibb Company
  • Cadila Healthcare Limited
  • Cipla Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • H. Lundbeck A/S
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Limited
  • TORRENT PHARMACEUTICALS LTD
  • UCB SA
Product Code: MRR-036C5CF3B54D

The Parkinson's Disease Therapeutics Market was valued at USD 5.81 billion in 2024 and is projected to grow to USD 6.14 billion in 2025, with a CAGR of 5.93%, reaching USD 8.21 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.81 billion
Estimated Year [2025] USD 6.14 billion
Forecast Year [2030] USD 8.21 billion
CAGR (%) 5.93%

Parkinson's disease continues to stand as one of the most challenging neurodegenerative conditions, demanding continuous innovation in therapeutic approaches. In recent years, research and clinical trials have led to both incremental and revolutionary advancements that not only address the motor symptoms but also the non-motor aspects of this complex condition. The evolving landscape of therapeutics has ushered a new era where precision medicine and personalized treatment plans are increasingly becoming integral to patient care. Current treatment paradigms are being reinforced by a deeper understanding of disease pathways, improved diagnostic techniques, and novel drug delivery methods that aim to reduce side effects and enhance patient outcomes.

This introduction sets the stage for a robust discussion on the multifaceted dynamics influencing Parkinson's disease therapeutics. It is important to note that continuous collaboration between clinicians, researchers, and industry experts is critical in defining the future course of therapy. By fostering a comprehensive perspective, stakeholders can better anticipate shifts in regulatory requirements, reimbursement models, and patient expectations. The convergence of science and technology is redefining treatment algorithms, offering hope to patients and caregivers alike. As we delve into the subsequent sections, this summary provides the necessary context by outlining the transformative shifts, segmentation insights, global regional dynamics, influential market players, and actionable recommendations that will inform strategic decisions in this evolving field.

Transformative Shifts in the Therapeutic Landscape

Recent years have brought transformative shifts in the therapeutic landscape of Parkinson's disease, reshaping old paradigms and introducing innovative treatment modalities. These shifts are driven by groundbreaking research that has redefined how therapeutic interventions are conceived and administered. Advances in neuropharmacology now enable more targeted modulation of the dopaminergic system, while emerging technologies offer improved precision in drug delivery. Driving this momentum are improved clinical trial designs, which have increasingly focused on long-term efficacy and safety, ensuring that novel therapies are both sustainable and accessible to a broader patient base.

Concurrently, an enhanced understanding of disease heterogeneity has forced practitioners to reconsider one-size-fits-all approaches. The industry is now emphasizing individualized treatment regimens that account for a patient's unique genetic and symptomatic profile. This personalization not only optimizes clinical outcomes but also helps in mitigating adverse effects associated with traditional therapies. Additionally, digital health solutions and remote patient monitoring are becoming integral in managing disease progression, enabling clinicians to adjust therapeutic strategies in near real time. Collaborative research across academic institutions and biotech companies is rapidly bridging the gap between laboratory discoveries and bedside applications, setting the stage for a period of unprecedented growth and innovation in Parkinson's therapeutics.

Key Insights from Market Segmentation

Market segmentation in the field of Parkinson's disease therapeutics provides critical insight into the myriad ways in which treatment strategies are being diversified to meet specific patient needs. The segmentation based on drug class involves a spectrum of treatment options studying anticholinergics, Carbidopa-Levodopa, COMT inhibitors, dopamine agonists, and MAO-B inhibitors. This classification facilitates a nuanced understanding of how different classes exert distinct therapeutic benefits and how they can be optimized for specific patient profiles.

Moreover, segmentation by route of administration highlights the significant roles played by intestinal infusion, oral methodologies, subcutaneous injections, and topical applications in achieving desired pharmacokinetic profiles. A further split based on drug form elucidates the impact of formulations such as injections, tablets and capsules, as well as transdermal patches on patient compliance and efficacy. Additionally, a targeted area segmentation sheds light on treatments associated with atypical Parkinsonian conditions, drug-induced Parkinsonism, genetic Parkinson's, idiopathic Parkinson's, and vascular Parkinsonism, emphasizing how variant presentations of the disease necessitate different therapeutic pathways. Lastly, the distribution channel segmentation, which evaluates hospital pharmacy, online pharmacy, and retail pharmacy outlets, is indicative of evolving consumer behaviors and adapting healthcare delivery models that ensure wider accessibility.

This detailed segmentation underscores the industry's drive to harness precision, tailor therapies more effectively, and ultimately improve the overall trajectory of patient care.

Based on Drug Class, market is studied across Anticholinergics, Carbidopa-Levodopa, COMT inhibitors, Dopamine Agonists, and MAO-B Inhibitors.

Based on Route Of Administration, market is studied across Intestinal Infusion, Oral, Subcutaneous, and Topical.

Based on Drug Form, market is studied across Injections, Tablets & Capsules, and Transdermal Patches.

Based on Targeted Area, market is studied across Atypical Parkinsonian, Drug-Induced Parkinsonism, Genetic Parkinson's, Idiopathic Parkinson's, and Vascular Parkinsonism.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Regional Dynamics Influencing Therapeutic Adoption

An analysis of the regional landscape uncovers significant variations in how Parkinson's disease therapeutics are adopted and integrated across different markets. The Americas have demonstrated a robust infrastructure backed by substantial investments in advanced research and state-of-the-art clinical practices. Meanwhile, regions encompassing Europe, the Middle East, and Africa are marked by proactive regulatory frameworks and a surge in collaborative alliances between governments and pharmaceutical innovators, thereby fostering an environment conducive to breakthrough therapies. In the Asia-Pacific region, rapid economic growth combined with increasing healthcare expenditure and a rising incidence of Parkinson's disease has driven remarkable advancements in treatment modalities and delivery systems.

These regional insights illustrate that while challenges remain in standardizing care across diverse healthcare settings, the evolving global landscape offers unique opportunities to harmonize research efforts and address patient needs more effectively. The interplay between regulatory reforms, funding allocations, and cultural nuances in each region further shapes the adoption curve and paves the way for strategic market entry and expansion.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Influential Companies Shaping the Market

Key market players are at the forefront of revolutionizing Parkinson's disease therapeutics, driving innovation and operational excellence in the sector. Industry leaders such as Apotex Inc. and Aurobindo Pharma Limited have consistently pushed the boundaries in generic formulation development, while companies like Biogen Inc. and Bristol-Myers Squibb Company leverage extensive research pipelines to deliver precision therapies. Cadila Healthcare Limited and Cipla Limited continue to strengthen their market presence through affordable yet effective treatment solutions.

Global pharmaceutical titans including Eisai Co., Ltd., Eli Lilly and Company, and GlaxoSmithKline plc have contributed significantly to the development of advanced drug formulations that emphasize both efficacy and patient convenience. In parallel, organizations such as Glenmark Pharmaceuticals Ltd., H. Lundbeck A/S, and Hikma Pharmaceuticals PLC are pivotal in initiating clinical studies that explore novel therapeutic mechanisms. Other influential companies like Lupin Limited, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, and Novartis AG have been instrumental in adapting to rapid market shifts through strategic investments in research and development. Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, TORRENT PHARMACEUTICALS LTD, and UCB S.A. are equally contributing to this dynamic scenario by pushing forward innovative treatments that cater to diverse patient demographics.

Together, these companies form an ecosystem that not only drives clinical advancements but also fosters a competitive environment where continual improvement becomes the norm, ensuring that patients benefit from the most updated and effective treatment strategies available.

The report delves into recent significant developments in the Parkinson's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma Limited, Biogen Inc, Bristol-Myers Squibb Company, Cadila Healthcare Limited, Cipla Limited, Eisai Co., Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Lupin Limited, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, TORRENT PHARMACEUTICALS LTD, and UCB S.A.. Actionable Recommendations for Industry Leaders

For stakeholders within Parkinson's disease therapeutics, strategic planning and investment are crucial in navigating this evolving market. Industry leaders are advised to concentrate on the development of therapies that not only address motor symptoms but also work to mitigate non-motor manifestations, thus offering holistic patient care. Identifying and capitalizing on emerging trends in precision medicine and targeted drug delivery will serve as key differentiators in an increasingly competitive arena. It is essential to invest in advanced research collaborations and clinical trials that explore multi-faceted treatment options, thereby reducing time-to-market for innovative drug solutions.

Fostering partnerships with academic institutions, biotech firms, and healthcare providers can greatly enhance the ability to personalize treatments for varied patient profiles. Leaders are encouraged to bolster digital platforms that support telemedicine and remote patient monitoring, enabling more efficient and timely adjustments in therapy regimens. Additionally, an emphasis on regulatory compliance, market authorization processes, and strategic communication with policymakers is critical to ensure seamless market entry and sustained growth. By streamlining operations and leveraging cutting-edge technological solutions, decision-makers can enhance patient engagement, optimize supply chain logistics, and ultimately secure a competitive advantage in a rapidly transforming market.

In summary, a forward-thinking approach that embraces innovation, collaboration, and adaptability will be key to transforming challenges into opportunities, ensuring long-term success in the therapeutic landscape.

Conclusion: Navigating the Evolving Therapeutic Sphere

The continuous evolution in Parkinson's disease therapeutics is a testament to the remarkable strides achieved by industry experts, researchers, and clinicians alike. As the treatment landscape expands, a multi-pronged approach that involves advanced drug formulations, innovative delivery systems, and personalized care models becomes indispensable. Reflection on the recent transformative shifts, detailed segmentation insights, profound regional dynamics, and influential market players reveals a sector in vigorous transformation.

The synthesis of robust clinical data, technological innovations, and strategic market insights underscores the potential for enhanced patient outcomes and improved quality of life. While challenges remain, the collaborative efforts across scientific, regulatory, and commercial domains represent a driving force that is reshaping the future of neurodegenerative disease management. With a commitment to continuous improvement and adaptive strategies, the industry is well-positioned to tackle the complexities inherent in Parkinson's disease, paving the way for more effective and patient-centric therapies.

Ultimately, this journey is not only about overcoming the limitations of current treatment paradigms but also about laying a solid foundation for tomorrow's breakthroughs. The integration of diverse insights and actionable strategies will continue to steer the industry toward a future where innovation serves as the cornerstone for better health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing elderly population with rising incidence rates of Parkinson's disease globally
      • 5.1.1.2. Emergence of personalized medicine approaches through biomarker identification and genetic research
      • 5.1.1.3. Enhanced healthcare infrastructure and improved access to specialized neurology centers
    • 5.1.2. Restraints
      • 5.1.2.1. High risk of adverse side effects reducing patient adherence and overall acceptance
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of AI algorithms and big data analytics to optimize predictive models for individualized treatment
      • 5.1.3.2. Rising investments in early diagnostic testing and advanced imaging techniques to facilitate timely detection
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory frameworks and meeting rigorous compliance standards across different region
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Growing preference for Lovopoda drug class to enhances the amount of levodopa entering the brain
    • 5.2.2. Targeted Area: Unraveling the neurological effects triggered by medication in drug-induced parkinsonism
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Parkinson's Disease Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anticholinergics
  • 6.3. Carbidopa-Levodopa
  • 6.4. COMT inhibitors
  • 6.5. Dopamine Agonists
  • 6.6. MAO-B Inhibitors

7. Parkinson's Disease Therapeutics Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Intestinal Infusion
  • 7.3. Oral
  • 7.4. Subcutaneous
  • 7.5. Topical

8. Parkinson's Disease Therapeutics Market, by Drug Form

  • 8.1. Introduction
  • 8.2. Injections
  • 8.3. Tablets & Capsules
  • 8.4. Transdermal Patches

9. Parkinson's Disease Therapeutics Market, by Targeted Area

  • 9.1. Introduction
  • 9.2. Atypical Parkinsonian
  • 9.3. Drug-Induced Parkinsonism
  • 9.4. Genetic Parkinson's
  • 9.5. Idiopathic Parkinson's
  • 9.6. Vascular Parkinsonism

10. Parkinson's Disease Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Americas Parkinson's Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Parkinson's Disease Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Parkinson's Disease Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Mitsubishi Tanabe Pharma America unveils three-tear data for ND0612 in parkinson's disease
    • 14.3.2. Vesalius and GSK forge alliance to Parkinson's treatment
    • 14.3.3. New immunoassay platform enhances parkinson's disease research
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Aurobindo Pharma Limited
  • 3. Biogen Inc
  • 4. Bristol-Myers Squibb Company
  • 5. Cadila Healthcare Limited
  • 6. Cipla Limited
  • 7. Eisai Co., Ltd.
  • 8. Eli Lilly and Company
  • 9. GlaxoSmithKline plc
  • 10. Glenmark Pharmaceuticals Ltd.
  • 11. H. Lundbeck A/S
  • 12. Hikma Pharmaceuticals PLC
  • 13. Lupin Limited
  • 14. Merck & Co., Inc.
  • 15. Mitsubishi Tanabe Pharma Corporation
  • 16. Novartis AG
  • 17. Otsuka Pharmaceutical Co., Ltd.
  • 18. Pfizer Inc.
  • 19. Sumitomo Dainippon Pharma Co., Ltd.
  • 20. Teva Pharmaceutical Industries Limited
  • 21. TORRENT PHARMACEUTICALS LTD
  • 22. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. PARKINSON'S DISEASE THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. PARKINSON'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PARKINSON'S DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA-LEVODOPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 241. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 242. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024